Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)
Dr. Scharschmidt joins Hyperion from NOVARTIS where he most recentlyserved as Vice President of Scientific Affairs for NOVARTIS Vaccines. Hepreviously held senior positions in Chiron's Corporate Group as well as inChiron's Vaccines and Biopharmaceuticals Development organizations where hewas intimately involved in the strategic direction and management of keyresearch and development programs. Before joining Chiron, Dr. Scharschmidtwas Chief of Gastroenterology and Professor of Medicine at the University ofCalifornia San Francisco. He is Board Certified in Internal Medicine andGastroenterology and has served as Associate Editor of Gastroenterology,Editor-in-Chief of The Journal of Clinical Investigation, and President of theAmerican Society for Clinical Investigation.
Advertisement
"Hyperion has made exceptional progress in a short time," commented Dr.Scharschmidt in discussing his new role. "I am enthusiastic about becomingpart of the organization and working with my colleagues both at Hyperion andin the GI and liver communities to bring products to patients in need."
"Bruce's technical expertise in gastroenterology and liver disease as wellas the drug development experience he gained at Chiron make him a significantasset in our company's effort to become a global leader in the development andcommercialization of hepatology and gastrointestinal therapies that addressorphan or underserved patient populations with unmet medical needs," saidChris Rivera, President and Chief Executive Officer of Hyperion Therapeutics,Inc. "We look forward to Bruce's many contributions."
About Hyperion Therapeutics
Hyperion Therapeutics is a fully-integrated specialty therapeutics companycommitted to becoming a global leader in the development and commercializationof hepatology and gastrointestinal therapies that address orphan orunderserved patient populations with unmet medical needs. Hyperion'scommercial operations division currently markets two products in the UnitedStates for urea cycle disorder. The Company is also conducting two phase IItrials, one in the chronic treatment of urea cycle disorder and the other inthe treatment of acute hepatic encephalopathy. Hyperion is headquartered inSouth San Francisco, CA. For additional information, visit:http://www.hyperiontx.com.
SOURCE Hyperion Therapeutics, Inc.
